Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

LLM-enabled Natural History Study Analysis to Support Rare Disease Research.

Created on 24 Sep 2026

Authors

Kevin Li, Eric Sid, Qian Zhu

Published in

medRxiv : the preprint server for health sciences. Sep 20, 2026. Epub Sep 20, 2026.

Abstract

Rare diseases affect an estimated 300 million people worldwide, yet the research needed to guide diagnosis and treatment is often fragmented across multiple unstructured literature sources. Natural history studies (NHS) are a key source of this evidence, but manually extracting structured information from NHS publications can be tedious and does not scale.
We have developed a proof-of-concept for an information extraction pipeline testing three opensource large-language models (LLMs) -- Athena-v3-AWQ, Google's Gemma3-27B, and Meta's Llama-3.1-70B-Instruct, to extract key NHS characteristics from PubMed abstracts curated from a Chan Zuckerberg Initiative disease research state model corpus (302 gold-standard and 8,338 full-corpus abstracts), and compared the models on efficiency, extraction completeness, and expert-rated accuracy.
All three models processed abstracts with success rates exceeding 99%. However, Gemma achieved the best overall performance, with the highest expert-rated accuracy (68.0% of outputs rated "good" vs. 36.0% for Llama and 10.0% for Athena) and the fastest runtime on the full corpus (~16 minutes for 3,547 abstracts), despite Llama scoring higher on the automated Token F1 metric (0.874 vs. 0.723), highlighting a divergence between automated and human evaluation. Athena's lower performance was largely attributable to verbatim copying rather than synthesis of extracted content.
These findings illustrate how locally deployed open-source LLMs can extract structured NHS characteristics at scale, thus supporting their use to accelerate evidence synthesis in rare disease research.

PMID:
42779962
Bibliographic data and abstract were imported from PubMed on 24 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement